UTIL OF HIGHLY SENS TSH-IRMA ASSAY FOR MONITORING SUPPRESSION OF PIT/AXIS

利用高灵敏度 TSH-IRMA 检测来监测凹陷/轴的抑制

• 批准号: 6308036
• 负责人: DOUGLAS S ROSS
• 金额: $ 0.06万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6308036
• 关键词: bone density; clinical research; clinical trial phase I; dosage; drug adverse effect; drug screening /evaluation; endocrine disorder chemotherapy; endocrine pharmacology; female; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; pituitary thyroid axis; thyroid disorder; thyroxine

This is a randomized prospective study to compare the efficacy of fully suppressive vs partially suppressive doses of 1-thyroxine in shrinking abnormal thyroid tissue, and to evaluate changes in bone density which may occur in patients taking suppressive doses of 1-thyroxine, and to determine if any documented adverse effects of 1-thyroxine on peripheral organs can be minimized by using partially suppressive, rather than fully suppressive doses of 1-thyroxine. Previous data by MGH investigators have suggested that ""suppressive"" doses of thyroxine may be asociated with osteoporosis. A highly sensitive (3rd generation) assay allows discrimination between partially and fully suppressive thyroxine doses. There are insufficient data to report any conclusions at the present time. Final data analysis will occur after all patients have been enrolled and prospectively followed. The investigators plan to continue to accrue data for all enrolled patients.

这是一项随机前瞻性研究，旨在比较完全抑制剂量与部分抑制剂量的1-甲状腺素在缩小异常甲状腺组织方面的疗效，并评估服用抑制剂量1-甲状腺素患者可能发生的骨密度变化，并确定是否可以通过使用部分抑制剂量，而不是完全抑制剂量的1-甲状腺素。 MGH研究者以前的数据表明，“抑制”剂量的甲状腺素可能与骨质疏松症有关。 高灵敏度（第3代）检测可区分部分和完全抑制甲状腺素剂量。目前没有足够的数据报告任何结论。最终数据分析将在所有患者入组并进行前瞻性随访后进行。研究者计划继续收集所有入组患者的数据。